

**Original article**

## **Clinical Presentations of *Helicobacter Pylori* (*H. Pylori*) Infections among Children of Western Uttar Pradesh Population, India**

**Dr. Shalabh Kumar Agarwal**

Associate Professor, Department of Paediatrics, TMMC& RC, Moradabad, UP, India.

Corresponding author: Dr. Shalabh Kumar Agarwal, Associate Professor, Department of Paediatrics, TMMC & RC, Moradabad, UP, India

---

### **Abstract**

**Introduction:** *H. pylori* is mostly acquired in the period of childhood. The prevalence of *H. pylori* is not homogenous worldwide; it varies depending on the patient's chronologic age, country of origin, ethnicity and socioeconomic background during childhood. This study aimed to determine the current prevalence and clinical outcomes of *H. pylori* infection in children.

**Materials and methods:** The study enrolled (200) cases divided into 2 groups; Patient (100 cases) and Control (100 cases) groups. The patient group was categorized in the basis of the presence of gastrointestinal symptoms for 3 months "Recurrent abdominal pain, chronic anorexia or recurrent vomiting", in addition to the documentation of *H. pylori* infection using *H. pylori* stool antigen test, ELISA and lastly, the Urea Breath Test (UBT) in cooperative children.

**Results:** From the total 100 Patients infected with *H. pylori*, 68 (68%), 22 (22%) and 10 (10%) cases presented with recurrent abdominal pain, anorexia and recurrent vomiting respectively compared to 22 (22%), 6 (6%) and 2 (2%) in control group (not infected with *H. pylori*). Recurrent abdominal pain, anorexia and recurrent vomiting are more significantly increased in patients infected with *H. pylori*, compared to non-infected cases "P<0.05, <0.02 and <0.05 respectively".

**Conclusion:** In children the infection with *H. pylori* is the initiator of vicious cycle of events that result ultimately in malnutrition and growth impairment with micronutrient deficiency. Further studies are needed to give more information about the clinical and therapeutic outcome of this apparent association in diverse pediatric populations with different *H. pylori* prevalences and risk factors.

**Key words:** *Helicobacter pylori* infections; ELISA, Urea breath test; *H. pylori* stool antigen test; anorexia, Recurrent abdominal pain.

---

### **Introduction**

*H. pylori* infection is witnessed in nearly 50% of the world's population. *H. pylori* is mostly acquired in the period of childhood, and its prevalence is higher in children from the lower socioeconomic strata.<sup>1,2</sup> Most children are colonized in early childhood, and in a substantial number of cases the infection will last many years unless the child is treated with appropriate antibiotics.<sup>3</sup>

Three different approaches elucidating the pathophysiology of such a negative effect have been suggested. First, malabsorption developing secondary to the suppression of gastric acid secretion leads to gastrointestinal infection and diarrhoea.<sup>4</sup> Second, a decreased appetite and malabsorption caused by *H. pylori* infection results in failure to thrive.<sup>5,6</sup> Finally, iron deficiency anemia due to *H. pylori* infection is also considered to impair growth.<sup>7,8</sup> Also, studies suggesting an association between *H. pylori*

infection and level of plasma ghrelin have recently been published.<sup>9</sup>

The list of disease entities with which the organism is causally related has increased to include recurrent abdominal pain, gastric mucosa-associated lymphoid tissue lymphoma, gastro-esophageal reflux disease, obesity, growth retardation, and, more recently, extragastric diseases such as coronary heart disease, normal tension glaucoma, and idiopathic thrombocytopenic purpura.<sup>10,11</sup> In developing countries, there is evidence that *H. pylori* can cause suppression of the gastric acid barrier, allowing enteropathogens ingested from contaminated weaning foods to gain access to the small intestine. This predisposes to childhood diarrhea, malabsorption of essential nutrients such as vitamins C and B12, and growth failure in childhood.<sup>12,13</sup>

Viable *H. pylori* organisms have never been isolated from the environment, hence interpersonal transmission is most likely. *H. pylori* seropositivity is more common in household contacts of infected children,<sup>14</sup> but the family contacts of infected adults do not show an increased risk of infection.<sup>15</sup> It is therefore uncertain whether the infection is mainly acquired from other family members. The prevalence of *H. pylori* is not homogenous worldwide; it varies depending on the patient's chronologic age, country of origin, ethnicity and socioeconomic background during childhood. There are vigorous innate and adaptive immune responses to *H. pylori* infection. Nevertheless, unless specific eradication therapy is provided, the gastric infection persists for lifetime.

*H. pylori* produce suspected disease - indicating factors, including urease (base of urea breath test), vacuolating cytotoxin, catalase and lipopolysaccharide (LPS). Urease is a potent antigen that induces increased IgG and IgA production.<sup>16</sup>

Catalase helps *H. pylori* survival in the host by preventing the formation of reactive oxygen metabolites from H<sub>2</sub>O<sub>2</sub>. The LPS outer membrane of *H. pylori* enhances the ability of organism to colonize the stomach.<sup>16</sup> Serological detection of *H. pylori* IgG antibodies is valuable in the assessment of children presenting with recurrent abdominal pain and other gastrointestinal symptoms. Children present an ideal population for studying the interaction between *H. pylori* and gastric mucosa because pediatric age is free from common causes of secondary gastrointestinal diseases (drugs, tobacco and alcohol).<sup>17</sup>

*H. pylori* infection can cause a deficiency of vitamins (such as vitamin C, vitamin A,  $\alpha$ -tocopherol, vitamin B12 and folic acid) and essential minerals. The relationship between obesity and *H. pylori* infection is controversial. This study aimed to determine the current prevalence and clinical outcomes of *H. pylori* infection among children in western Uttar Pradesh region.

#### **Materials and methods**

This study was conducted prospectively at the general outpatient clinic of the Department of Paediatrics, in Teerthanker Mahaveer Medical College and Research Centre, Moradabad, UP, India. Approval of this study was received from the administration of TMU Hospital, Moradabad. Daily written consent for laboratory test from each case was taken from the parents of children. The study enrolled (200) cases divided into 2 groups; Patient (100 cases) and Control (100 cases) groups. The patient group was categorized in the basis of the presence of gastrointestinal symptoms for 3 months "Recurrent abdominal pain, chronic anorexia or recurrent vomiting", in addition to the documentation of *H. pylori* infection using *H. pylori*

stool antigen test, ELISA and lastly, the Urea Breath Test (UBT) in cooperative children. Cases of hematologic disorders “e.g. sickle cell anemia”, collagen vascular diseases or children on antibiotics two weeks ago as well as patients with past or family history of psychic element were excluded from the research. Urea Breath Test was done for certain selected cases (i.e.) cases with recurrent abdominal pain more than one year with negative serology and practically if cooperating. The control cases were defined by the absence of IgG antibodies to *H. pylori*. Complete blood count and serum ferritin were investigated to document refractory iron deficiency anemia. All patients had been ranged from 5-12 years old and matched with control for age, sex and sociodemographic factors.

Individuals infected with *H. pylori* develop antibodies that correlate strongly with histologically confirmed *H. pylori* infection.<sup>18</sup> The one step *H. pylori* test device (Serum/Plasma) is simple test that utilizes combination of *H. pylori* antigen coated particles and anti-human IgG, qualitatively and selectively detect *H. pylori* antibodies in serum or plasma. It is rapid chromatographic immunoassay without cross reactivity indicating high degree of specificity.<sup>19</sup> Moreover, there was a rather good correlation between the enzyme-linked immunosorbent assay (ELISA) antibody test and the rapid urease test, which did not provide further information to the diagnosis of *H. pylori*.<sup>20</sup>

The one step *H. pylori* Antigen Test Device (Feces) is another a rapid chromatographic immunoassay (providing results in 10minutes) for the qualitative detection of *H. pylori* antigen in human feces specimens to aid in the diagnosis of *H. pylori* infections.<sup>21</sup>

**Urea Breath Test (UBT)**-The patient should be fasting for 4 hours prior to the test. The patient swallows capsule containing 14 C-Urea with 50 ml water. Peak time is typically 10-30 minutes. This test has been shown to be an extremely accurate method of detecting *H. pylori* infection because it has the advantage of evaluating the gastric mucosa as a whole. Multiple studies have shown that (UBT) has both high sensitivity and high specificity for diagnosing active *H. pylori* infection in children.<sup>20</sup> It is demonstrated that the noninvasive tests 13C-UBT and *H. pylori* stool antigen are highly concordant and specific for the diagnosis of *H. pylori* infection in children of all ages.<sup>22</sup> Breath Tek UBT for *H. pylori* has Excellent Sensitivity (95.5%) and Specificity (96.0%) for Confirming Eradication.<sup>23</sup>

Both tests were easy to perform and are readily available.

Data were analyzed with SPSS. T-test and Chi-square were used for data analysis. Odd ratios and confidence interval with 95% were calculated. *P* value less than 0.05 was considered statistically significant.

**Result**

Group	Recurrent Abdominal Pain	Recurrent Vomiting	Anorexia
-Patient ( <i>H. pylori</i> +ve)	<b>68 (68%)</b>	<b>22 (22%)</b>	<b>10 (10%)</b>
-Control ( <i>H. pylori</i> -ve)	<b>22 (22%)</b>	<b>6 (6%)</b>	<b>2 (%)</b>
P value	P value=<0.05	P value=<0.02	P value=<0.05

Table 1: Distribution of patients and control based on clinical presentation and Laboratory investigations

Group	Weight (kg)	Height (cm)	Sideropenic Anemia
Patient (no.=120) <i>H. pylori</i> +ve	19.4 ± 2	126.1 ± 1.6	<b>38 (38%)</b>
Control (no=100) <i>H. pylori</i> -ve)	<b>26.6 ± 2.4</b>	<b>138 ± 2.9</b>	<b>18 (18%)</b>
<b>P value =&lt;0.05</b>	<b>P value =&lt;0.02</b>	<b>P value =&lt;0.01</b>	<b>P value =&lt;0.05</b>

Table 2: Distribution of patient and control groups according to malnutrition.

From the total 100 Patients infected with *H. pylori* , 68 (68%), 22 (22%) and 10 (10%) cases presented with recurrent abdominal pain, anorexia and recurrent vomiting respectively compared to 22 (22%), 6 (6%) and 2 (2%) in control group (not infected with *H. pylori* ). As shown in Table 1. *H. pylori* infections in children commonly present with various phenotypic clinical features that were chronic abdominal pain, vomiting and anorexia (i.e.) persisted three months or more. Recurrent abdominal pain, anorexia and recurrent vomiting are more significantly increased in patients infected with *H. pylori*, compared to non-infected cases “P<0.05, <0.02and <0.05 respectively”. Regarding the complications related to *H. pylori* infection, patient group demonstrated

significant reduction in weight (19.4 ± 2 kg) and height (126.1 ± 1.6 c m) compared to control weight (26.6 ± 2.4 kg) and height (138 ± 2 cm). In sideropenic (or refractory iron deficiency anemia) the number of anemic children was 38(38%) whereas, the number was 18(18%) in control group Table 3. Recurrent abdominal pain, anorexia and recurrent vomiting are more significantly increased in patients infected with *H. pylori*, compared to non-infected cases “P<0.05, <0.02and <0.05 respectively”.

**Discussion**

Our study on the effect of *H. pylori* infection in early life has Show that the Differences between patients and controls are significant regarding weight, height and sideropenic anemia. During childhood, *H. pylori*

is associated with predominant antral gastritis, and duodenal ulcers.<sup>24,25</sup> Successful eradication of *H. pylori* markedly reduces the rate of recurrence of duodenal ulcers in affected children.<sup>26,27</sup> Gastric ulcers are much less common in children than they are in adults.<sup>28</sup>

Two years later, Dufouret *al*<sup>29</sup> reported a 7-year-old child who presented with *H. pylori*-associated chronic antral gastritis without evidence of hemorrhage or clinical symptoms other than sideropenic anemia, which was refractory to oral iron administration and subsided after *H. pylori* eradication. These case reports were followed by other studies that have identified an association between *H. pylori* infection and pediatric unexplained or refractory IDA, and have indicated improvement of iron stores and anemia after successful *H. pylori* eradication.<sup>30-36</sup> Yet, some pediatric studies have implicated *H. pylori* as a cause of IDA that is refractory to oral iron treatment.<sup>30,31,36</sup>

Many studies support the role of *H. pylori* in the development of refractory iron – deficiency (sideropenic) anemia.<sup>37,38</sup> Interestingly, sideropenic anemia is not associated with hematemesis or tarry stools, suggesting that long-standing *H. pylori* infection itself can cause anemia in the absence of active bleeding from the gastrointestinal tract.<sup>39</sup>

In the prospective, longitudinal study by Bravo *et al*,<sup>1</sup> lower-middle class children from Colombia, in general good health, aged 1-5 years, who tested negative by urea breath test at baseline, were monitored over the following 2.5 years for anthropometric measurements every 2 mo, and for *H. pylori* by urea breath test every 4 mo. The deceleration of growth velocity took place 1 to 2 mo after the onset of infection, and after adjusting for age the slower growth rate was a fairly constant  $0.042 \pm$

$0.014$  cm/mo ( $P = 0.003$ ) less than that of uninfected children. The effect of *H. pylori* infection on growth velocity (0.5 cm/year) led to an accumulated growth deficit, which was not compensated after the infection had been established for more than 6 mo. No interactions between growth velocity, *H. pylori* status and the time of exposure, or other socioeconomic variables were observed. As expected,<sup>40</sup> a limitation of this study was the high intrasubject variability of growth velocity.

In a cohort of urban Colombian preschool children, in good general health, with a median follow-up of about 500 d, Mera *et al*<sup>41</sup> prospectively investigated whether a newly acquired *H. pylori* infection had transient or permanent effects on growth. Breath tests and anthropometric measurements were performed every 2 to 4 mo. The authors observed that the impact of a new infection on growth velocity was more pronounced during the first 4 mo after infection.

Egorov *et al*<sup>42</sup> prospectively assessed the potential effects of new *H. pylori* infection (defined as positive fecal antigen test and negative serology) on linear and ponderal growth in low socioeconomic status young children living in poor suburbs of Quito, Ecuador. Normally nourished, mildly and substantially malnourished children (defined using weight-for-age *z*-scores at recruitment) formed one-third each of the study population. Six height and weight measurements were collected during one year. The main finding of this study was that new *H. pylori* infections were associated with reduced linear growth in young children. Several studies have shown negative associations of *H. pylori* with asthma, allergy, and atopic diseases,<sup>43-51</sup> additional studies are needed to examine the strength of the evidence linking disorders in children to *H. pylori*, and to

better understand mechanisms on how *H. pylori* affects them in childhood.

**Conclusion:**

Our study showing that gastric *H. pylori* infection, growth faltering and iron deficiency anemia are essentially interrelated pathogenic factors. Infection with *H. pylori* in children is the initiator of vicious

cycle of events that result ultimately in malnutrition and growth impairment with micronutrient deficiency. Many more studies are needed to provide more information about the clinical and therapeutic outcome of this apparent association in diverse pediatric populations with different *H. pylori* prevalences and risk factors.

**References**

1. Bravo LE, Mera R, Reina JC, Pradilla A, Alzate A, Fonham E, et al. Impact of *Helicobacter pylori* infection on growth of children: a prospective cohort study. *J Pediatr Gastroenterol Nutr* 2003;37:614-619.
2. Passaro DJ, Taylor DN, Gilman RH, Cabrera L, Parsonnet J. Growth slowing after acute *Helicobacter pylori* infection is age dependent. *J Pediatr Gastroenterol Nutr* 2002;35:522-526.
3. Ford AC, Axon ATR. Epidemiology of *Helicobacter pylori* infection and Public Health Implications. *Helicobacter*. 2010; 15(SUPPL. 1):1-6. [PubMed: 21054646]
4. Thomas JE, Dale A, Bunn JE, Harding M, Coward WA, Cole TJ, et al. Early *Helicobacter pylori* colonisation: the association with growth faltering in The Gambia. *Arch Dis Child* 2004;89:1149-1154.
5. Soylyu OB, Ozturk Y. *Helicobacter pylori* infection: effect on malnutrition and growth failure in dyspeptic children. *Eur J Pediatr* 2008;167:557-562.
6. Ozçay F, Demir H, Ozen H, Gürakan F, Saltik IN, Yüce A, et al. Normal growth in young children with *Helicobacter pylori* infection. *J Pediatr Gastroenterol Nutr* 2002;35:102.
7. Choe YH, Kim SK, Hong YC. *Helicobacter pylori* infection with iron deficiency anaemia and subnormal growth at puberty. *Arch Dis Child* 2000;82:136-140.
8. Cuoco L, Cammarota G, Jorizzo RA, Cianci R, Gasbarrini G. Iron deficiency anaemia, *Helicobacter pylori* infection and delayed pubertal growth. *Arch Dis Child* 2000;83:456.
9. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A (2011) Extragastric manifestations of *Helicobacter pylori* infection. *Helicobacter* 16 Suppl 1: 65-69.
10. Dale A, Thomas JE, Darboe MK, Coward WA, Harding M, Weaver LT (1998) *Helicobacter pylori* infection, gastric acid secretion, and infant growth. *J Pediatr Gastroenterol Nutr* 26: 393-397.
11. Vitale G, Barbaro F, Ianiro G, Cesario V, Gasbarrini G, Franceschi F, Gasbarrini A (2011) Nutritional aspects of *Helicobacter pylori* infection. *Minerva Gastroenterol Dietol* 57: 369-377.
12. Epplein M, Signorello LB, Zheng W, Cai Q, Hargreaves MK, Michel A, Pawlita M, Fowke JH, Correa P, Blot WJ (2011) *Helicobacter pylori* prevalence and circulating micronutrient levels in a low income United States Population. *Cancer Prev Res (Phila)* 4: 871-878.
13. Drumm B, Rerez PG, Blaser MJ, Sherman PM. Intrafamilial clustering of *Helicobacter pylori* infection. *N Engl J Med* 1990;322:359-63.

14. Jones DM, Eldridge J, Whorwell PJ. Antibodies to *Campylobacter pyloridis* in household contacts of infected patients. *BMJ* 1987;294:61-5.
15. Maria TriantafylloPoulo (2008) *Helicobacter pylori* infection, overview with *Medicine Pediatr: General Medicine*.
16. Crabtree JE, Mahony MJ, Taylor JD, Heatley RV, Littlewood JM, et al. (1991) Immune responses to *Helicobacter pylori* in children with recurrent abdominal pain. *J ClinPathol* 44: 768-771.
17. Sabbi T, De Angelis P, Colistro F, Dall'Oglio L, di Abriola GF, et al. (2005) Efficacy of noninvasive tests in the diagnosis of *Helicobacter pylori* infection in pediatric patients. *Arch PediatrAdolesc Med* 159: 238-241.
18. Pronovost AD, Rose SL, Pawlak JW, Robin H, Schneider R (1994) Evaluation of a new immunodiagnostic assay for *Helicobacter pylori* antibody detection: correlation with histopathological and microbiological results. *J ClinMicrobiol* 32: 46-50.
19. Acon (2005) Lab Inc. USA. San Diego, CA 92121 No: 1150.
20. Janulaityte-Gunther D, Kucinskiene R, Kupcinskis L, Pavilonis A, Labanauskas L, et al. (2005) The humoral immune response to *Helicobacter pylori* infection in children with gastrointestinal symptoms. *FEMS Immunol Med Microbiol* 44: 205-212.
21. ACON Laboratories, Inc. 4108 Sorrento Valley Boulevard, San Diego, CA 92121, USA. Package Insert. Number 1150399901, 2007
22. Costa Cardinali LDC, Rocha GA, Magalhães Queiro DM (2003) Evaluation of [<sup>13</sup>C]Urea Breath Test and *Helicobacter pylori* Stool Antigen Test for Diagnosis of *H. pylori* Infection in Children from a Developing Country. *J ClinMicrobiol* 41: 3334-3335.
23. Package Insert for BreathTek UBT. Otsuka America Pharmaceutical, Inc; 2012.
24. Sherman P, Czinn S, Drumm B, Gottrand F, Kawakami E, Madrazo A, Oderda G, Seo JK, Sullivan P, Toyoda S, Weaver L, Wu TC. *Helicobacter pylori* infection in children and adolescents: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. *JPediatrGastroenterolNutr* 2002; 35 Suppl 2: S128-S133
25. Blecker U. *Helicobacter pylori*-associated gastroduodenal disease in childhood. *South Med J* 1997; 90: 570-576; quiz 577
26. Goggin N, Rowland M, Imrie C, Walsh D, Clyne M, Drumm B. Effect of *Helicobacter pylori* eradication on the natural history of duodenal ulcer disease. *Arch Dis Child* 1998; 79: 502-505
27. Chiesa C, Pacifico L, Anania C, Poggiogalle E, Chiarelli F, Osborn JF. *Helicobacter pylori* therapy in children: overview and challenges. *Int J ImmunopatholPharmacol* 2010; 23: 405-416
28. Macarthur C, Saunders N, Feldman W. *Helicobacter pylori*, gastroduodenal disease, and recurrent abdominal pain in children. *JAMA* 1995; 273: 729-734
29. Dufour C, Brisigotti M, Fabretti G, Luxardo P, Mori PG, Barabino A. *Helicobacter pylori* gastric infection and sideropenic refractory anemia. *J PediatrGastroenterolNutr* 1993; 17: 225-227
30. Ashorn M, Ruuska T, Mäkiperna A. *Helicobacter pylori* and iron deficiency anaemia in children. *Scand J Gastroenterol* 2001; 36: 701-705

31. Barabino A, Dufour C, Marino CE, Claudiani F, De Alessandri A. Unexplained refractory iron-deficiency anemia associated with *Helicobacter pylori* gastric infection in children: further clinical evidence. *J PediatrGastroenterolNutr*1999; 28: 116-119
32. Carnicer J, Badía R, Argemí J. *Helicobacter pylori* gastritis and sideropenic refractory anemia. *J PediatrGastroenterolNutr*1997; 25: 441
33. Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, Lahad A. Role of autoimmune gastritis, *Helicobacter pylori* and celiac disease in refractory or unexplained iron deficiency anemia. *Haematologica*2005; 90: 585-595
34. Konno M, Muraoka S, Takahashi M, Imai T. Iron-deficiency anemia associated with *Helicobacter pylori* gastritis. *J PediatrGastroenterolNutr*2000; 31: 52-56
35. Kostaki M, Fessatou S, Karpathios T. Refractory iron-deficiency anaemia due to silent *Helicobacter pylori* gastritis in children. *Eur J Pediatr*2003; 162: 177-179
36. Russo-Mancuso G, Branciforte F, Licciardello M, La Spina M. Iron deficiency anemia as the only sign of infection with *Helicobacter pylori*: a report of 9 pediatric cases. *Int J Hematol*2003; 78: 429-431
37. Annibale B, Capurso G, DelleFave G (2003) The stomach and iron deficiency anaemia: a forgotten link. *Dig Liver Dis* 35: 288-295.
38. Sherman PM (2004) Appropriate strategies for testing and treating *Helicobacter pylori* in children: when and how? *Am J Med* 117 Suppl 5A: 30S-35S.
39. Kato S, Nishino Y, Ozawa K, Konno M, Maisawa S, et al. (2004) The prevalence of *Helicobacter pylori* in Japanese children with gastritis or peptic ulcer disease. *J Gastroenterol* 39: 734-738.
40. WHO Working Group. Use and interpretation of anthropometric indicators of nutritional status. WHO Working Group. *Bull World Health Organ.* 1986;64:929-941. [[PMC free article](#)][[PubMed](#)]
41. Mera RM, Correa P, Fonham EE, Reina JC, Pradilla A, Alzate A, Bravo LE. Effects of a new *Helicobacter pylori* infection on height and weight in Colombian children. *Ann Epidemiol.* 2006;16:347-351. [[PubMed](#)]
42. Egorov AI, Sempértegui F, Estrella B, Egas J, Naumova EN, Griffiths JK. The effect of *Helicobacter pylori* infection on growth velocity in young children from poor urban communities in Ecuador. *Int J Infect Dis.* 2010;14:e788-e791. [[PubMed](#)]
43. 158. Matricardi PM, Rosmini F, Riondino S, Fortini M, Ferrigno L, Rapicetta M, Bonini S. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. *BMJ.*2000;320:412-417. [[PMC free article](#)][[PubMed](#)]
44. Herbarth O, Bauer M, Fritz GJ, Herbarth P, Rolle-Kampczyk U, Krumbiegel P, Richter M, Richter T. *Helicobacter pylori* colonisation and eczema. *J Epidemiol Community Health.* 2007;61:638-640. [[PMC free article](#)][[PubMed](#)]
45. Linneberg A, Ostergaard C, Tvede M, Andersen LP, Nielsen NH, Madsen F, Frølund L, Dirksen A, Jørgensen T. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. *J Allergy ClinImmunol.* 2003;111:847-853. [[PubMed](#)]



46. Kosunen TU, Höök-Nikanne J, Salomaa A, Sarna S, Aromaa A, Haahtela T. Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to *Helicobacter pylori* infections. *ClinExp Allergy*. 2002;32:373–378. [[PubMed](#)]
47. Janson C, Asbjornsdottir H, Birgisdottir A, Sigurjonsdottir RB, Gunnbjörnsdottir M, Gislason D, Olafsson I, Cook E, Jögi R, Gislason T, et al. The effect of infectious burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and Sweden. *J Allergy Clin Immunol*. 2007;120:673–679. [[PubMed](#)]
48. Shiotani A, Miyanishi T, Kamada T, Haruma K. *Helicobacter pylori* infection and allergic diseases: epidemiological study in Japanese university students. *J GastroenterolHepatol*. 2008;23:e29–e33. [[PubMed](#)]
49. von Hertzen LC, Laatikainen T, Mäkelä MJ, Jousilahti P, Kosunen TU, Petays T, Pussinen PJ, Haahtela T, Vartiainen E. Infectious burden as a determinant of atopy-- a comparison between adults in Finnish and Russian Karelia. *Int Arch Allergy Immunol*. 2006;140:89–95. [[PubMed](#)]
50. Chen Y, Blaser MJ. Inverse associations of *Helicobacter pylori* with asthma and allergy. *Arch Intern Med*. 2007;167:821–827. [[PubMed](#)]
51. McCune A, Lane A, Murray L, Harvey I, Nair P, Donovan J, Harvey R. Reduced risk of atopic disorders in adults with *Helicobacter pylori* infection. *Eur J GastroenterolHepatol*. 2003;15:637–640. [[PubMed](#)]